Current recommendations for genetic testing from the Danish Breast Cancer Group (DBCG) are consistent with national guidelines across Europe and focus on the family predisposition, early age onset of BC (under 50 years), bilateral BC, Triple Negative (TNBC), that is, oestrogen receptor-negative (ER-), human epidermal growth factor receptor 2 (HER2)-negative, progesterone receptor (PR)-negative and/or basal-like molecular subtype, BC and OC in the same patient and male BC [4, 7]. Here, ERBB2 is linked to breast carcinoma.